+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis?



Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis?



Clinical Journal of the American Society of Nephrology 8(1): 138-145



Most patients with SLE develop kidney disease related to this systemic underlying disease process. Lupus nephritis is an important cause of morbidity and even mortality in patients with systemic lupus erythematosus. Lupus nephritis has diverse morphologic manifestations with varying clinical presentations and consequences. The pathogeneses involve immune complexes, which can deposit anywhere in the kidney, and other mechanisms, including endothelial injury, podocytopathy, and tubulointerstitial injury. Treatment and prognosis accordingly range from excellent even with only observation with minimal mesangial deposits, to kidney failure despite aggressive immunosuppression in patients with severe proliferative disease. Renal biopsy plays a crucial role in the diagnosis of the specific form of lupus nephritis in any patient. However, the role of the renal biopsy in prediction of outcome, treatment, and prognosis has been controversial. We will review the current classification of lupus nephritis and the value of renal biopsy in the management of these patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 036707709

Download citation: RISBibTeXText

PMID: 22977215

DOI: 10.2215/CJN.03400412



Related references

The role of kidney biopsy in the management of lupus nephritis. Current Opinion in Nephrology and Hypertension 14(1): 1-8, 2004

The role of kidney biopsy in the management of lupus nephritis. Current Opinion in Nephrology & Hypertension 14(1): 1-8, 2005

Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group. American Journal of Kidney Diseases 21(4): 374-377, 1993

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. American Journal of Kidney Diseases 61(5): 710-715, 2013

Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Progress in Clinical and Biological Research 337: 301-307, 1990

Kidney biopsy in lupus nephritis: look before you leap. Nephrology, Dialysis, Transplantation 21(7): 1749-1752, 2006

The kidney biopsy in lupus nephritis: is it still relevant?. Rheumatic Diseases Clinics of North America 40(3): 537-52, Ix, 2015

Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis. Arthritis Research and Therapy 13(6): R199, 2012

OP0045Efficacy of the Euro-Lupus Nephritis Regimen Combined with Abatacept VS Placebo in A North American Lupus Nephritis Population. Annals of the Rheumatic Diseases 73(Suppl 2): 77.3-78, 2014

Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Annals of the Rheumatic Diseases 68(2): 234-237, 2008

Lupus nephritis treated with a cytostatic agent. A case of systemic lupus erythematosus with lupus nephritis treated with 6-mercaptopurine. Danish Medical Bulletin 13(6): 151-154, 1966

A case report of lupus nephritis associated with minimal change nephrotic syndrome--comparison of various histological types of 67 cases with lupus nephritis. Nihon Jinzo Gakkai Shi 34(7): 835-840, 1992

Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis and Rheumatology 67(5): 1305-1313, 2015

Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Annals of Internal Medicine 114(11): 924-929, 1991

Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 22(6): 574-582, 2013